Both IL-6 and tissue inhibitor of metalloproteinase 1 (Timp1) were remarkably released in the thymus upon doxorubicin treatment, a step leading to the establishment of a “chemoresistant niche,” which in turn allowed the survival of residual lymphoma cells as a minimal residue disease and ultimately caused disease relapse.98 The gene discussed is TIMP1; the disease is lymphoma.